Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Short-term Investments (2024 - 2025)

Caris Life Sciences has reported Short-term Investments over the past 2 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Short-term Investments at $1.5 million for Q4 2025, down 30.71% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (down 30.71% YoY), and the annual figure for FY2025 was $1.5 million, down 30.71%.
  • Short-term Investments for Q4 2025 was $1.5 million at Caris Life Sciences, roughly flat from $1.5 million in the prior quarter.
  • Over the last five years, Short-term Investments for CAI hit a ceiling of $2.2 million in Q4 2024 and a floor of $1.5 million in Q2 2025.